Related Experiment Video
Updated: Jul 4, 2026

In Vitro Model of Coronary Angiogenesis
Published on: March 10, 2020
[Crow-Fukase syndrome and VEGF]
Kimiyoshi Arimura1, Teruto Hashiguchi, Osamu Watanabe
1Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medicine, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.
Crow-Fukase syndrome (CFS/POEMS) involves polyneuropathy and elevated vascular endothelial growth factor (VEGF). High VEGF levels are key to diagnosis and pathogenesis, and stem cell transplantation effectively reduces VEGF and improves neuropathy.
Area of Science:
- Neurology
- Oncology
- Vascular Biology
Context:
- Crow-Fukase syndrome (CFS/POEMS) is characterized by chronic sensorimotor polyneuropathy and systemic symptoms.
- Elevated serum vascular endothelial growth factor (VEGF) is a diagnostic marker and implicated in CFS/POEMS pathogenesis.
Purpose:
- To explore the role of VEGF in CFS/POEMS pathogenesis.
- To evaluate novel therapeutic strategies, including stem cell transplantation, for CFS/POEMS.
Summary:
- Human glioblastoma xenografts in mice induce high VEGF levels, edema, and organ pathology, mimicking CFS/POEMS.
- VEGF may contribute to polyneuropathy via blood-nerve barrier disruption and microangiopathy.
- High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) shows significant efficacy, rapidly decreasing VEGF and improving neuropathy.
Impact:
- VEGF is identified as a central molecule in CFS/POEMS pathogenesis.
- PBSCT offers a promising therapeutic approach, demonstrating rapid and sustained reduction in VEGF levels.
- VEGF serves as a crucial biomarker for both diagnosis and treatment monitoring in CFS/POEMS.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis
TGF - β Signaling Pathway
Cushing Syndrome II: Pathophysiology
Cytotoxic Edema: Pathophysiology
Cerebral Edema ll: Pathophysiology

